Liu Yan, Yang Yan, Chen Yalin, Zhou Linyue, Xiong Qian, Xie Chunguang
Hospital of Chengdu University of Traditional Chinese Medicine.
Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China.
Medicine (Baltimore). 2020 Sep 4;99(36):e21806. doi: 10.1097/MD.0000000000021806.
DM is a common chronic metabolic disease. COVID-19 is an infectious disease infected by enveloped single-stranded RNA coronavirus. Meanwhile, DM is a common comorbidity of SARS-CoV-2 infection. The virus can directly or indirectly damage the pancreatic islets and cause stress hyperglycemia by causing cytokine storms, acute inflammatory reactions, binding to the ACE2 receptor, etc. At the same time, hyperglycemia is a risk factor for severe infection and an independent risk factor for mild to severe disease. However, there is no evidence-based medicine to confirm the relationship between hyperglycemia and the infection of COVID-19 in diabetic patients. Therefore, we will conduct a systematic review and meta-analysis to synthesize the existing clinical evidence.
We will retrieve each database from December 2019 to July 2020. Chinese literature comes from CNKI, Wanfang, VIP, CBM databases. English literature mainly searches Cochrane Library, PubMed, Web of Science, EMBASE. At the same time, we will look for clinical trial registration and gray literature. This study only included clinical randomized controlled trials. The reviewers independently conduct literature selection, data analysis, bias risk assessment, subgroup and sensitivity analysis. The primary outcomes include fasting blood glucose, 2-hour postprandial blood glucose, glycated hemoglobin, fasting insulin, adverse effects, etc. Finally, we will conduct a meta-analysis through Review Manager software version 5.3.
The results will be published in peer-reviewed journals.
This study will explore the relationship between hyperglycemia and COVID-19 infection in diabetic patients. It will provide evidence-based support for clinical regulation of blood glucose and combating the COVID-19 epidemic.
INPLASY202060114.
糖尿病是一种常见的慢性代谢性疾病。新型冠状病毒肺炎是一种由包膜单链RNA冠状病毒感染引起的传染病。同时,糖尿病是严重急性呼吸综合征冠状病毒2感染的常见合并症。该病毒可直接或间接损害胰岛,并通过引发细胞因子风暴、急性炎症反应、与血管紧张素转换酶2受体结合等导致应激性高血糖。同时,高血糖是严重感染的危险因素,也是疾病从轻症发展为重症的独立危险因素。然而,尚无循证医学证实糖尿病患者高血糖与新型冠状病毒肺炎感染之间的关系。因此,我们将进行一项系统评价和荟萃分析,以综合现有的临床证据。
我们将检索2019年12月至2020年7月的各个数据库。中文文献来自中国知网、万方、维普、中国生物医学文献数据库。英文文献主要检索考克兰图书馆、PubMed、科学网、EMBASE。同时,我们将查找临床试验注册信息和灰色文献。本研究仅纳入临床随机对照试验。评审员独立进行文献筛选、数据分析、偏倚风险评估、亚组分析和敏感性分析。主要结局包括空腹血糖、餐后2小时血糖、糖化血红蛋白、空腹胰岛素、不良反应等。最后,我们将通过Review Manager 5.3版软件进行荟萃分析。
结果将发表在同行评审期刊上。
本研究将探讨糖尿病患者高血糖与新型冠状病毒肺炎感染之间的关系。它将为临床血糖调控和抗击新型冠状病毒肺炎疫情提供循证支持。
INPLASY202060114。